Allakos Inc. (ALLK)

Market Cap	83.91M
Revenue (ttm)	n/a
Net Income (ttm)	-178.75M
Shares Out	89.34M
EPS (ttm)	-2.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	551,092
Open	0.997
Previous Close	1.010
Day's Range	0.912 - 1.040
52-Week Range	0.540 - 3.410
Beta	1.02
Analysts	Hold
Price Target	1.67 (+77.81%)
Earnings Date	Nov 6, 2024

About ALLK

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 19, 2018
• Employees: 131
• Stock Exchange: NASDAQ
• Ticker Symbol: ALLK
• Website: https://www.allakos.com

Analyst Forecast

According to 5 analysts, the average rating for ALLK stock is "Hold." The 12-month stock price forecast is $1.67, which is an increase of 77.81% from the latest price.

Price Target

$1.67

(77.81% upside)

Analyst Consensus: Hold